Polycythemia vera screening
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera screening On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera screening |
|
Risk calculators and risk factors for Polycythemia vera screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
Screening for polycythemia vera is not a routine clinical practice. However, assessment of a complete blood count (CBC), which is done routinely, usually gives the first indication for the presence of polycythemia vera in a patient.
Screening
There is no role for screening for polycythemia vera. In order to diagnose a suspected case of polycythemia vera, JAK2 mutational analysis can be done from the peripheral blood. Cell-based quantitative assays for JAK2 V617F mutation may be helpful among patients with the following:[1]
The complete blood count (CBC), which includes quantitation of red blood cells, white blood cells, and platelets, is typically done routinely in people, and an elevated hemoglobin is sometimes the first laboratory indication for a diagnosis of polycythemia vera.
References
- ↑ Tefferi A, Noel P, Hanson CA (2011). "Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology". J Mol Diagn. 13 (5): 461–6. doi:10.1016/j.jmoldx.2011.05.007. PMC 3157620. PMID 21723416.